1-12 of 12
David R. Newell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine

William Douglas Figg, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2525–2529.
https://doi.org/10.1158/1078-0432.CCR-14-0511
Published: 14 May 2014
View article titled, Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
Open the PDF for Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine in another window
Journal Articles

Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia

Alan V. Boddy, Julieann Sludden, Melanie J. Griffin, Colin Garner, John Kendrick, Pritesh Mistry, Catherine Dutreix, David R. Newell, Stephen G. O'Brien
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4164–4169.
https://doi.org/10.1158/1078-0432.CCR-06-2179
Published: 18 July 2007
View article titled, Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia
Open the PDF for Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia in another window
Journal Articles

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

E. Ruth Plummer, Mark R. Middleton, Christopher Jones, Anna Olsen, Ian Hickson, Peter McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3402–3409.
https://doi.org/10.1158/1078-0432.CCR-04-2353
Published: 02 May 2005
View article titled, Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Open the PDF for Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 in another window
Journal Articles

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

Nicola J. Curtin, Lan-Zhen Wang, Anthie Yiakouvaki, Suzanne Kyle, Christine A. Arris, Stacie Canan-Koch, Stephen E. Webber, Barbara W. Durkacz, Hilary A. Calvert, Zdenek Hostomsky, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 881–889.
https://doi.org/10.1158/1078-0432.CCR-1144-3
Published: 10 February 2004
View article titled, Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells
Open the PDF for Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells in another window
Journal Articles

Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies

Christopher R. Calabrese, Michael A. Batey, Huw D. Thomas, Barbara W. Durkacz, Lan-Zhen Wang, Suzanne Kyle, Donald Skalitzky, Janke Li, Catherine Zhang, Theodore Boritzki, Karen Maegley, Alan H. Calvert, Zdenek Hostomsky, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2711–2718.
Published: 01 July 2003
View article titled, Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: <subtitle>Chemopotentiation and Pharmacological Studies</subtitle>
Open the PDF for Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: <subtitle>Chemopotentiation and Pharmacological Studies</subtitle> in another window
Journal Articles

Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy

Gareth J. Veal, Cinara Dias, Lisa Price, Annie Parry, Julie Errington, Juliet Hale, Andrew D. J. Pearson, Alan V. Boddy, David R. Newell, Michael J. Tilby
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2205–2212.
Published: 01 August 2001
View article titled, Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy
Open the PDF for Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy in another window
Journal Articles

The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs

Xiaohong Lu, Julie Errington, Nicola J. Curtin, John Lunec, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2114–2123.
Published: 01 July 2001
View article titled, The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs
Open the PDF for The Impact of <em>p53</em> Status on Cellular Sensitivity to Antifolate Drugs in another window
Journal Articles

In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity

Peter G. Smith, Huw D. Thomas, Hannah C. Barlow, Roger J. Griffin, Bernard T. Golding, A. Hilary Calvert, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2105–2113.
Published: 01 July 2001
View article titled, <em>In Vitro</em> and <em>in Vivo</em> Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity
Open the PDF for <em>In Vitro</em> and <em>in Vivo</em> Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity in another window
Journal Articles

Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines

Xiaohong Lu, Julie Errington, Victor J. Chen, Nicola J. Curtin, Alan V. Boddy, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 271–277.
Published: 01 January 2001
View article titled, Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines
Open the PDF for Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines in another window
Journal Articles

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Carol A. Delaney, Lan-Z Wang, Suzanne Kyle, Alex W. White, A. Hilary Calvert, Nicola J. Curtin, Barbara W. Durkacz, Zdenek Hostomsky, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2860–2867.
Published: 01 July 2000
View article titled, Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines
Open the PDF for Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines in another window
Journal Articles

Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of de Novo Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines

Matthew J. Barnes, Edward J. Estlin, Gordon A. Taylor, G. Wynne Aherne, A. Hardcastle, J. J. McGuire, Joanne A. Calvete, John Lunec, Andrew D. J. Pearson, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2548–2558.
Published: 01 September 1999
View article titled, Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines
Open the PDF for Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines in another window
Journal Articles

Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days

Andy N. Hughes, Imran Rafi, Melanie J. Griffin, A. Hilary Calvert, David R. Newell, Joanne A. Calvete, Amanda Johnston, Neil Clendeninn, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 111–118.
Published: 01 January 1999
View article titled, Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days
Open the PDF for Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days in another window